期刊文献+

冠心病患者可溶性OX40配体与白细胞介素10的相关性分析 被引量:1

Correlation between plasma soluble sOX40L and IL-10 levels in patients with stable coronary heart disease
在线阅读 下载PDF
导出
摘要 目的观察冠心病稳定型心绞痛患者及高危因素患者和健康人血浆可溶性OX40配体(sOX40L)和白细胞介素10(IL-10)水平及两者之间的相关性,探讨sOX40L在冠心病中的作用及其相关因素。方法采用酶联免疫吸附法测定35例稳定型心绞痛患者、30例高危因素患者以及20名健康人血浆中sOX40L及IL-10的水平。结果稳定型心绞痛患者血浆OX40L水平[(24.95±15.60)ng/L]高于健康对照组[(16.44±11.31)ng/L],差异有统计学意义(P<0.05),略高于高危因素组[(19.99±9.35)ng/L],但差异无统计学意义(P>0.05)。与健康对照组相比,稳定型心绞痛组IL-10水平显著降低[(27.3±9.9)ng/L比(20.5±8.9)ng/L,P<0.05]。血浆sOX40L与IL-10呈显著负相关(r=-0.394,P=0.000)。结论本研究首次观察到血浆可溶性OX40L水平与抗炎细胞因子IL-10的水平呈显著负相关,提示sOX40L可能通过影响IL-10的水平而影响冠心病的危险程度。 Objective To investigate the relationship between plasma soIuble OX40L(sOX40L) and Interleukin- 10 (IL-10) levels in patients with stable coronary heart disease. Methods Plasma sOX40L and IL-10 levels were determined by enzyme-linked immunosorbent assay in 35 patients with stable angina pectoris, 30 individuals with risk factors of coronary heart disease and 20 healthy controls. Results The sOX40L level was significantly higher in patients with stable angina than in healthy control group [ ( 24. 95 ± 15.60 ) ng/L vs. ( 16.44 ± 11.31 ) ng/L, P 〈 0. 05 ] . Compared with control group, the level of plasma IL-10 significantly decreased in stable angina group [ (27. 3 ± 9. 9)ng/L vs. ( 20. 5 ± 8.9 ) ng/L, P 〈 0. 05 ]. Blood sOX40L level were negatively correlated with IL-10 ( r = - 0. 394, P = 0. 000). Conclusions Plasma sOX40L level was negatively correlated with IL-10. OX40L may increase the risk of CHD by inhibiting IL-10 secretion.
出处 《中国心血管杂志》 2009年第4期278-281,共4页 Chinese Journal of Cardiovascular Medicine
关键词 冠状动脉疾病 OX40配体 白细胞介素10 Coronary disease OX40 ligand Interleukin-10
作者简介 通讯作者:彭道泉,电子信箱:pengdq@hotmail.com
  • 相关文献

参考文献1

二级参考文献15

  • 1赵水平.高密度脂蛋白的研究现状[J].中国动脉硬化杂志,2005,13(6):673-675. 被引量:22
  • 2Mendel I,Shevach EM.Activated T cells express the OX40 ligand:requirements for induction and costimulatory function.Immunology,2006,117:196-204.
  • 3Wang X,Ria M,Kelmenson PM,et al.Positional identification of TNFSF4,encoding OX40 ligand,as a gene that influences atherosclerosis susceptibility.Nat Genet,2005,4:365-372.
  • 4Ria M,Eriksson P,Boquist S,et al.Human genetic evidence that OX40 is implicated in myocardial infarction.Biochem Biophys Res Commun,2006,339:1001-1006.
  • 5Croft M.Co-stimulatory members of the TNFR family:keys to effective T-cell immunity? Nat Rev Immunol,2003,3:609-620.
  • 6Imura A,Hori T,Imada T,et al.The human OX40/gp34 system directly mediates adhesion of activated T cells to vascular endothelial cells.J Exp Med,1996,183:2185-2195.
  • 7Sugamura k.Ishii N,Weinberg AD.Therapeutic targeting if the effector T-cell co-stimulatory molecule OX40.Nat Rev Immunol,2004,4:420-431.
  • 8Paigen B,Albee D,Holmes PA,et al.Genetic analysis of murine strains C57BL/6J and C3H/HeJ to confirm the map position of Ath-1,a gene determining atherosclerosis susceptibility.Biochem Genet,1987,25:501-511.
  • 9Paigen B,Mitchell D,Reue K,et al.Ath-1,a gene determining atherosclerosis susceptibility and high density lipoprotein levels in mice.Proc Natl Acad Sci U S A,1987,84:3763-3767.
  • 10Libby P.Inflammation in atherosclerosis.Nature,2002,420:868-874.

共引文献24

同被引文献9

  • 1Yan JC, Liu DM, Wang CP, et al. Increased levels of soluble and membrane-bound OX40 ligand in patients with acute coronary syndrome. Biomed Pharmacother, 2008, Sep 17.
  • 2Liu DM,Yan JC, Wang CP, et al. The clinical implications of increased OX40 ligand expression in patients with acute coronary syndrome. Clin Chim Acta, 2008, 397:22-26.
  • 3van Wanrooij EJ, van PuijveldeGH, de Vos P, et al. Interruption of theTnfrsf4/Tnfsf4 (OX40/OX40L) pathway attenuates atherogenesis in low-density lipoprotein receptor-deficient mice. Arterioscler Thromb Vasc Biol, 2007, 27 : 204- 210.
  • 4Ria M,Eriksson P, Boquist S, et al. Human genetic evidence that OX40 is implicated in myocardial infarction. Biochem Biophys Res Commun, 2006, 339 : 1001-1006.
  • 5Wojnicz R,Wilczek K, Nowalany-Kozielska E, et al. Usefulness of atorvastatin in patients with heart failure due to inflammatory dilated cardiomyopathy and elevated cholesterol levels. Am J Cardiol, 2006, 97:899-904.
  • 6Ludwig A,Friedel B, Metzkow S, et al. Effect of statins on the proteasomal activity in mammalian endothelial and vascular smooth muscle cells. Biochem Pharmaeol, 2005, 70:520-526.
  • 7Lindahl B, Toss H, Siegbahn A, et al. Markers of myocardial damage and inflammation in relation to long-term mortality in unstable coronary artery disease. N Engl J Med, 2000, 343: 1139-1147.
  • 8RidkerPM, Rifai N, Pfeffer MA, et al. Inflammation, pravastatin, and the risk of coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events (CARE) Investigators. Circulation, 1998, 98:839-844.
  • 9Ridker PM,Danielson E, Fonseca FA, et al. Reduction in C- reactive protein and LDL cholesterol and cardiovascular event rates after initiation of rosuvastatin: a prospective study of the JUPITER trial. Lancet, 2009, 373 : 1147-1148.

引证文献1

二级引证文献1

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部